September 4, 2012
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Dr.
, Ph.D. will join the Board of Directors on
, 2012. On joining the Board, Dr. Gillis will become a member of the Company's Science & Technology Committee and Remuneration Committee.
Dr. Gillis is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH's biotechnology portfolio companies. Prior to this, Dr. Gillis was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corporation.
An immunologist by training, Dr. Gillis has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL.
He received his B.A. from
in 1975 and his Ph.D. from
Dr. Gillis is a Non-Executive Director of Genesis Research and Development Corporation Limited., a
and Australian Stock Exchange-listed biotechnology company. He was a Non- Executive Director and then Executive Chairman and Acting President of Trubion Pharmaceuticals Inc., until its sale in 2010.
"Steven's pioneering and entrepreneurial approach paired with a deep technical and scientific knowledge will complement the existing skills and outlook of the Shire Board. I look forward to him joining in the autumn."